Volume 43, Issue 6 pp. 1291-1301
ORIGINAL ARTICLE

Hemophagocytic histiocytosis in severe SARS-CoV-2 infection: A bone marrow study

Himanshu Dandu

Himanshu Dandu

Department of Internal Medicine, King George’s Medical University, Lucknow, India

Search for more papers by this author
Geeta Yadav

Corresponding Author

Geeta Yadav

Department of Pathology, King George’s Medical University, Lucknow, India

Correspondence

Geeta Yadav, Department of Pathology, King George’s Medical University, Lucknow, India.

Email: [email protected]

Search for more papers by this author
Hardeep Singh Malhotra

Hardeep Singh Malhotra

Department of Neurology, King George’s Medical University, Lucknow, India

Search for more papers by this author
Saurabh Pandey

Saurabh Pandey

Department of Internal Medicine, King George’s Medical University, Lucknow, India

Search for more papers by this author
Ruovinuo Sachu

Ruovinuo Sachu

Department of Pathology, King George’s Medical University, Lucknow, India

Search for more papers by this author
Kinjalk Dubey

Kinjalk Dubey

Department of Internal Medicine, King George’s Medical University, Lucknow, India

Search for more papers by this author
First published: 04 June 2021
Citations: 9

Abstract

Introduction

The clinical and laboratory features of severe COVID-19 infection overlap with those of hemophagocytic lymphohistiocytosis (HLH), a hyperinflammatory disorder often associated with several viral infections. The clinical syndrome of HLH encompasses fever, organomegaly, cytopenias, hyperferritinemia, hypertriglyceridemia, raised transaminases, hypofibrinogenemia, absent natural killer (NK) cell activity, increased soluble CD25 and hemophagocytic lymphohistiocytosis in bone marrow, spleen, and lymph nodes.

Methods

We analyzed clinicopathological and laboratory features of thirteen patients with severe COVID-19 infection suspected to have HLH and found to have hemophagocytic histiocytosis on bone marrow examination (BME).

Results

Five of thirteen (38.46%) patients fulfilled five of eight HLH 2004 criteria and/or had a H-score ≥169. Three (23.08%) satisfied four of eight and remainder five (38.46%) satisfied three of eight HLH 2004 criteria. Fever, raised serum ferritin (13/13, 100%), transaminases (9/13, 69.23%), triglycerides (4/13, 30.76%), cytopenias (5/13, 38.46%), hypofibrinogenemia (2/13, 15.38%), and organomegaly (1/13, 7.69%) were observed in our patients. BME showed hemophagocytic histiocytosis without lymphocytosis in all. Contrary to HLH, lymphocytopenia (11/13, 84.61%), leukocytosis (7/13, 53.84%), neutrophilia (7/13, 53.84%), and hyperfibrinogenemia (7/13, 53.84%) were observed. Serum CRP, LDH, and plasma D-dimer were elevated in all, while serum albumin was decreased in 12 of 13 (92.3%) patients. Five patients recovered with high-dose pulsed corticosteroid therapy.

Conclusion

The immune response associated with severe COVID-19 infection is similar to HLH with few differences. HLH should be suspected in severe COVID-19 infection although all patients may not fulfill required HLH diagnostic criteria. BME should be done in suspected cases so that appropriate therapy may be initiated early.

CONFLICT OF INTEREST

The authors have no competing interests.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.